Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the efficacy and safety of lenalidomide maintenance therapy in
patients with T-cell lymphoma who have undergone more than one treatment or relapsed after
treatment and who acquired a response of more than a partial response after rescue
chemotherapy. This is a phase 2 clinical trial.